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2ABSTRACT
When blood is exposed to variety of artificial surfaces and biologic substances, the plasma proteins factor
XII (FXII) and prekallikrein undergo reciprocal proteolytic conversion to the proteases FXIIa and -
kallikrein by a process called contact activation. These enzymes contribute to host-defense responses
including coagulation, inflammation, and fibrinolysis. The initiating event in contact activation is debated.
To test the hypothesis that single-chain FXII expresses activity that could initiate contact activation, we
prepared human FXII variants lacking the Arg353 cleavage site required for conversion to FXIIa (FXII-
R353A), or lacking the three known cleavage sites at Arg334, Arg343, and Arg353 (FXII-T, for “triple”
mutant), and compared their properties to wild type FXIIa. In the absence of a surface, FXII-R353A and
FXII-T activate prekallikrein and cleave the tripeptide S-2302, demonstrating proteolytic activity. The
activity is several orders of magnitude weaker than that of FXIIa. Polyphosphate, an inducer of contact
activation, enhances PK activation by FXII-T, and facilitates FXII-T activation of FXII and factor XI. In
plasma, FXII-T and FXII-R353A, but not FXII lacking the active site serine residue (FXII-S544A),
shortened the clotting time of FXII-deficient plasma and enhanced thrombin generation in a surface-
dependent manner. The effect was not as strong as for wild type FXII. Our results support a model for
induction of contact activation in which activity intrinsic to single-chain FXII initiates FXIIa and -
kallikrein formation on a surface. FXIIa, with support from -kallikrein, subsequently accelerates contact
activation and is responsible for the full procoagulant activity of FXII.
KEY POINTS
o The single chain form of Factor XII, a component of the plasma contact system, has proteolytic activity.
o Single-chain FXII activity suggests a mechanism for initiation of contact activation when blood is
exposed to physiologic or artificial surfaces.
INTRODUCTION
3The cascade/waterfall hypotheses proposed by Macfarlane and by Davie and Ratnoff in 1964 describe
plasma coagulation as a series of proteolytic steps culminating in thrombin-mediated conversion of
fibrinogen to fibrin [1,2]. Coagulation is initiated in these models by activation of factor XII (FXII) when
blood is exposed to a suitable surface [1-3]. These investigators postulated that FXII undergoes changes
upon surface binding that form or expose an active site. It is now clear that a variety of substances promote
reciprocal proteolytic conversion of FXII and prekallikrein (PK) to the proteases -factor XIIa (FXIIa)
and -kallikrein by a process called contact activation [4-6]. FXIIa then promotes coagulation by
converting factor XI (FXI) to factor XIa (FXIa). While patients lacking FXII do not have a bleeding disorder
[7], the protein contributes to pathologic coagulation particularly when blood is exposed to artificial
surfaces, such as during cardiopulmonary bypass, extracorporeal membrane oxygenation, and after
placement of intravascular devices [8-15]. In animal models, FXII contributes to thrombosis [16-20], with
anionic polymers such as polyphosphate (Poly-P) and nucleic acids probably serving as counterparts to the
non-biologic surfaces used to induce contact activation in vitro [17,21-25].
Despite progress in our understanding of the pathophysiology of contact activation, the processes that
initiate FXII activation remain uncertain. Several triggering mechanisms have been proposed that are not
mutually exclusive. Contact activation could be initiated by traces of FXIIa, -kallikrein, or other
proteases that may always be present in plasma [26-28]. Alternatively, single-chain FXII may have activity,
either intrinsically or after binding to a surface, that starts the process [29-31]. Here we show that a form of
FXII that is not converted to FXIIa has proteolytic activity, and that the activity is enhanced in the presence
of Poly-P. The results suggest a mechanism for initiation of surface-induced coagulation that does not
depend on pre-existing FXIIa or -kallikrein.
EXPERIMENTAL PROCEDURES
Materials. Normal plasma; Precision BioLogic. FXII-deficient plasma; George King Biomed. FXII, FXIIa,
PK, -kallikrein and corn trypsin inhibitor (CTI); Enzyme Research Lab. S-2302 (H-D-prolyl-L-
phenylalanyl-L-arginine-p-nitroaniline); DiaPharma. PTT-A reagent; Diagnostica Stago. Synthetic Poly-P
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Thomas Renné and Katrin Nikel (Karolinska Institute). Monoclonal IgGs to FXI (O1A6) [32], FXIIa
(559C-X181-D06 [D06]) [33], and kallikrein (559A-M202-H03 [H03]) [33,34] have been described. Goat
polyclonal IgGs against FXII, PK, and FXI were from Affinity Biologicals.
Recombinant Proteins. Schematic diagrams of human FXII, PK and FXI and their cleaved forms are shown
in Fig.1A. A FXI cDNA with the active site serine replaced with alanine (FXI-S557A) was expressed in
HEK293 cells using vector pJVCMV, purified by IgG affinity chromatography, and stored in 4 mM Tris-
HCl 150 mM NaCl pH 7.4 [35]. FXII [36] and PK [37] cDNAs were introduced into pJVCMV and
expressed in HEK293 cells under serum free conditions (Supp. data 1). In addition to wild type FXII (FXII-
WT), variants were made with alanine replacing arginine at each known cleavage site (FXII-R334A, FXII-
R343A or FXII-R353A) or all three cleavage sites (FXII-T for “triple” mutant), or replacing the active site
serine (FXII-S544A). Wild type PK (PK-WT) and variants with alanine replacing arginine at the activation
site (PK-R371A) or the active site serine (PK-S559A) were also prepared. FXII and PK were purified by
anion exchange chromatography (Fig.1B) as described under Supp. data 1.
Chromogenic assays (continuous assay). Assays were conducted in microtiter plate wells coated with
PEG-20,000 to prevent induction of contact activation. Activation of FXII (200 nM) and/or PK (200 nM)
in 100 L of standard buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% PEG-8000, 10 M ZnCl2) at
37 ºC. Reactions contained 200 M S-2302 and changes in OD 405 nm were monitored on a microplate
reader. Some reactions contained Poly-P (70 M) or 10% PTT-A reagent. S-2302 (1.6 to 1000 M)
cleavage by 5 nM FXIIa or 200 nM fXII-T was studied under similar conditions. Rates of OD405 nm
were converted to p-nitroanaline formed (extinction coefficient for pNA 9920 M−1 cm−1). Km and kcat were
determined by non-linear least squares fitting using Scientist Software (Micromath). (discontinuous assay).
FXII activation (200 nM) with Poly-P (70 M) or α-kallikrein (50 nM), and PK (12.5 to 600 nM) cleavage 
by FXIIa (25 pM) or FXII-T (15 nM) were performed in standard buffer at 37 ºC. For FXII activation,
reactions were stopped with Polybrene (0.1 mg/ml) with or without H03 (10 nM). For PK cleavage,
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nm) was monitored. Amounts of FXIIa or kallikrein formed were determined with standard curves prepared
with pure protease.
Western blots. Reactions were conducted in polypropylene tubes coated with PEG-20,000. FXII (200 nM)
with or without PK (200 nM), FXI (30 nM), or -kallikrein (50 nM) was incubated at 37 ºC in standard
buffer at 37 ºC. Some reactions contained 70 M Poly-P or PTT-A reagent (25% final volume). At various
times, aliquots were removed and mixed with SDS-sample buffer. Samples were size fractionated by SDS-
PAGE (12% acrylamide) and transferred to nitrocellulose membranes. Blots of reduced proteins were
probed with polyclonal IgG to FXII, PK, or FXI. Non-reducing blots were probed with antibodies that
preferentially recognize FXIIa (D06) or kallikrein (H03). For all blots, detection was with an HRP-
conjugated secondary antibody and chemiluminescence.
Clotting assays. FXII-deficient plasma (30 μL) was mixed with 30 μL FXII (400 nM) in PBS. PTT-A 
reagent (30 μL) was added followed by incubation for 5 min at 37 °C. 25 mM CaCl2 (30 μL) was added, 
and time to clot formation was measured on an ST-4 Analyzer (Diagnostica Stago). Results were compared
to those for normal plasma. Means  1 SD were compared by Mann-Whitney test.
Thrombin Generation. Thrombin generation was measured in 96-well polypropylene plates on a
Fluoroskan Ascent analyzer as described [35]. FXII-deficient plasma was supplemented with FXII (200
nM), 415 M Z-Gly-Gly-Arg-AMC, 1.6 M CTI or vehicle, 20 ug/ml of IgG O1A6 or vehicle, and PTT-
A reagent (13% final volume). Supplemented plasma (40 l) was mixed with 10 l of 20 mM HEPES pH
7.4, 100 mM CaCl2, 6% BSA and fluorescence (excitation  390 nm, emission  460 nm) was monitored.
Carotid artery thrombosis model. Procedures with mice were approved by the Vanderbilt University
Animal Care and Use Committee. FXII-deficient C57Bl/6 mice [16] were anesthesthetized with 50 mg/kg
IP pentobarbital. The right common carotid artery was exposed and fitted with a Doppler probe (Model 0.5
VB, Transonic System). FXII (25 g in 100 uL of PBS) was infused through the internal jugular vein. Five
6minutes later two 1 x 1.5 mm filter papers (GB003, Schleicher & Schuell,) saturated with 5% FeCl3 were
applied to opposite sides of the artery for three min [18]. Flow was monitored for 30 min.
RESULTS
FXII autoactivation. FXII undergoes autocatalytic activation in the presence of several polyanions
[17,21,26-29]. The Coomassie-stained reducing gel in Fig.2A shows the 80 kDa FXII polypeptide
undergoing autocatalysis in the presence of Poly-P, forming the 50 kDa heavy and 30 kDa light chains of
FXIIa. The changes are accompanied by a rapid increase in amidolytic activity (Fig.2B). FXII is cleaved
at up to three sites during activation (after Arg334, Arg343, or Arg353 Fig.1A). Cleavage after Arg353 is
required for FXIIa generation [36,38]. FXII species with Arg353 (FXII-WT, FXII-R334A. FXII-R343A)
undergo autocatalysis in the presence of Poly-P, while species lacking Arg353 (FXII-R353A and FXII-T)
do not (Fig.2C, middle column). Loss of the catalytic active site serine (Ser544) [36], as expected, also
prevents autocatalysis (Fig.2C, middle column). Experiments examining cleavage of the tripeptide S-2302
support the western blot data, with amidolytic activity increasing in reactions with species that undergo
conversion to FXIIa, but not in reactions with FXII-R353A, FXII-T or FXII-S544A (Fig.2D). These data
show that cleavage after Arg353 is required for full elaboration of FXII amidolytic activity.
FXII activation by -kallikrein. During contact activation, -kallikrein cleaves FXII after Arg353 forming
FXIIa [36,38]. Substitutions for Arg334 or Arg343 do not prevent this (Fig.2C, right column). -
kallikrein also cleaves FXII-R353A (Fig.2C, right column); however, this does not increase amidolytic
activity (Fig.2E), indicating cleavage is after a residue other than 353. Because Arg353 replacement did
not prevent FXII cleavage, we prepared FXII-T, which lacks all three known FXII cleavage sites. The
failure of -kallikrein to cleave FXII-T (Fig.2C, right column) indicates -kallikrein cleaves FXII-R353A
after Arg334 and/or Arg343. FXII-S544A, which has Arg353, is cleaved by -kallikrein (Fig.2C, right
column) but, as expected, also lacks amidolytic activity because of the absence of Ser544 (Fig.2E). We
performed non-reducing western blots for reactions similar to those in the right hand column of Fig.2C
using IgG D06, which preferentially recognizes fully formed FXIIa (Supp. data 2). Signals are detected
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confirms that when FXII-R353A is cleaved by kallikrein it does not assume a conformation similar to
FXIIa. Cumulatively, the results support the premise that full FXIIa amidolytic activity requires cleavage
after Arg353 and an active catalytic mechanism (i.e. Ser544).
Reciprocal FXII and PK activation. Mixing FXII and PK in the absence of a surface leads to cleavage of
both proteins as revealed by reducing western blots (Fig.3A). Each protein undergoes more than one
cleavage, but at least one involves the respective activation sites (after FXII Arg353 or PK Arg371) [38].
This is shown in the non-reducing blots in Fig.3B, which use antibodies that preferentially recognize fully
formed FXIIa (D06) and kallikrein (H03) [33,34]. Taken as a whole, the reducing and non-reducing blots
indicate FXII is converted first to FXIIa (80 kDa) by cleavage after Arg353, then more slowly to FXIIa
(30 kDa) by cleavage after Arg334 (Fig.1A). PK is converted to -kallikrein by cleavage after Arg371, and
then -kallikrein by cleavage after Arg140 (Fig.1A), both of which are 90 kDa proteins (Fig.3B) [37,38].
Mixing FXII-WT and PK-WT generates patterns similar to their plasma counterparts (Fig.3C).
Unexpectedly, forms of FXII that do not form FXIIa (FXII-R353A and FXII-T) induce PK cleavage
(Fig.3C). The results could not be accounted for by endogenous FXII production by HEK293 cells, nor by
non-FXII constituents of conditioned media (Supp. data 1). Furthermore, PK-WT was not cleaved by FXII-
S544A (Fig.3C), indicating cleavage requires recombinant FXII with an intact FXII catalytic apparatus.
The variant PK-S559A, which lacks an active site serine, was also cleaved by FXII-R353A and FXII-T,
indicating -kallikrein activity is not needed for PK cleavage in reactions with FXII-R353A and FXII-T
(Supp. data 3). These data show that single-chain FXII has proteolytic activity.
S-2302 cleavage by single-chain FXII. Single-chain FXII-WT cleaves S-2302 at a low rate (Fig.4A). This
is usually interpreted as reflecting traces of contaminating FXIIa, a possibility that cannot be ruled out.
However, FXII-R353A and FXII-T also consistently demonstrated low-level amidolytic activity, while
FXII-S544A does not (Fig.4A). S-2302 is cleaved by FXIIa with Km 10010 M and kcat 70020/min
(Fig.4B), and by FXII-T with Km 27003300 M, kcat 6.56.4/min (Fig.4C). The results indicate that
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(Fig.4I), an estimate that should be considered an approximation, as the apparent Km for the FXII-T-
mediated reaction is greater than the achievable substrate concentration. While addition of silica-based
PTT-A reagent (Fig.4D) or Poly-P (Fig.2D) increased amidolytic activity with FXII-WT because of
conversion to FXIIa, neither compound enhanced the amidolytic activity of FXII-R353A or FXII-T.
PK activation by single-chain FXII. In mixtures of FXII and PK, amidolytic activity reflects FXIIa and
kallikrein generation, as both proteases cleave S-2302. This is shown in Fig.4E for mixtures of FXII-WT
and PK-WT. Mixing PK with FXII-R353A or FXII-T also generates amidolytic activity (Fig.4E). As these
FXII species cleave S-2302 poorly (Fig.2E) and do not formFXIIa, the amidolytic activity must be largely
due to PK conversion to kallikrein by cleavage after Arg371. In support of this, neither FXII-R353A nor
FXII-T cleaved PK lacking Arg371 (PK-R371A, Supp. data 4). Reactions containing PK alone or PK
mixed with FXII-R544S generate little amidolytic activity (Fig.4E), demonstrating the importance of a
functional FXII catalytic domain. FXIIa activates PK with Km 0.170.03 M and kcat 444/min (Fig.4F),
while FXII-T activates PK with Km 0.800.06 M and kcat 0.00370.0002/min (Fig.4G). The catalytic
efficiency (kcat/Km Fig.4I) of FXII-T-mediated PK activation is ~50,000-fold lower than for FXIIa.
Consistent with observations that polyanions accelerate reciprocal FXII/PK activation [31,33], PK
activation by FXII-T is enhanced by Poly-P (Fig.4H).
Single-chain FXII catalyzes surface-dependent FXII activation. Neither FXII-T nor FXII-S544A undergo
autocatalysis in the presence of Poly-P (Fig.2C), the former because it lacks cleavage sites and the later
because it lacks catalytic activity. When these proteins are mixed in the presence of a silica-based aPTT
reagent or Poly-P (Fig.5A) there is a time-dependent increase in a signal on western blots using IgG D06,
indicating formation of a species with a catalytic domain with similar conformation to FXIIa. Incubation
of either protein alone with Poly-P does not produce a signal, consistent with results in Fig.2C (middle
column). Of the two proteins, only FXII-S544A cleaved after Arg353 is recognized well by IgG D06 (Supp.
Data 2). Therefore, the results are most consistent with surface-induced FXII-T cleavage of FXII-S544A
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bound to an activating surface.
Single-chain FXII catalyzes surface-dependent FXI activation. FXIIa-mediated conversion of FXI to
FXIa is a key step in contact activation-initiated coagulation. In the following experiments FXI-S557A is
used instead of FXI because the latter undergoes autoactivation when exposed to polyanions [35] making
it difficult to assess the FXII contribution to FXI activation. In the absence of Poly-P, mixing FXI-S557A
with FXII-WT, FXII-T or FXII-S544A does not result in detectable FXI-S557A cleavage (Fig.5B top row).
With Poly-P (Fig.5B bottom row), FXII-WT converts FXI-S557A to a two-chain species representing FXIa.
This is consistent with FXII-WT undergoing autoactivation, and FXIIa-WT then cleaving FXI-S557A. In
the presence of Poly-P, FXII-T but not FXII-S544A cleaved FXI-S557A to the two-chain form, indicating
that single-chain FXII possesses activity that activates FXI on a surface.
Single-chain FXII activity in plasma. In aPTT assays, the clotting time of normal and FXII-deficient
plasma were 401 and 32730 seconds, respectively. Adding forms of FXII that can be converted to FXIIa
substantially shortened the aPTT of FXII-deficient plasma (FXII-WT [402 sec], FXII-R334A [411 sec]
or FXII-R343A [511 sec] Fig.6A). FXII-R353A and FXII-T, which do not form FXIIa, also shortened
the aPTT of FXII-deficient plasma (2025 and 16419 sec, respectively, p<0.0001 for both compared with
FXII-deficient plasma), but not to the same extent as FXII-WT. FXII-S544A did not affect the clotting time
significantly (3026 sec, p=0.2). FXII-WT and plasma FXII support thrombin generation in FXII-deficient
plasma supplemented with PTT-A reagent comparably (Fig.6B). FXII-T also supports thrombin generation,
but the peak is smaller and delayed compared to FXII-WT (Fig.6C), while FXII-S544A did not support
thrombin generation. The effects of FXII-WT and FXII-T on thrombin generation were blocked by the FXII
inhibitor CTI and the FXIa inhibitor O1A6 (Fig.6D), showing that single-chain FXII promotes thrombin
generation by activating FXI in the presence of a surface.
FXII and arterial thrombosis. FXII-deficient mice are protected from carotid artery thrombosis induced
by application of FeCl3 to the vessel exterior (Fig.7) [18]. Infusion of FXII-WT, as expected, restored
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FeCl3-induced carotid artery occlusion in FXII-deficient mice. In contrast, FXII-R353A, FXII-T and FXII-
S544A failed to support thrombosis, with the exception of one of nine animals supplemented with FXII-T.
These data are consistent with results from plasma the assays, and indicate that the relatively small amount
of thrombin generated through the proteolytic activity of single-chain FXII is not sufficient to promote
thrombosis in this model, and that FXIIa is required for full elaboration of protease activity.
DISCUSSION
FXII becomes active when blood is exposed to a variety of biologic and non-biologic substances, however,
the mechanism that initiates activation is debated. Given the range of surfaces that support contact
activation, different processes may operate in different situations [39]. In 1976, Griffin and Cochrane raised
the question of whether a proteolytic or non-proteolytic process best explained initial FXII activity [40].
Several groups proposed that FXII gains activity once surface-bound, and postulated that conversion to a
two-chain form is not required in all circumstances [29-31]. Silverberg et al. [26,27] and Tans et al. [28]
came to a different conclusion. In their opinions FXIIa was the active form of FXII, and the sigmoidal
progress curves for surface-dependent FXII autoactivation were most compatible with a process initiated
by traces of FXIIa in FXII preparations. However, recognizing the difficulty of eliminating other
possibilities with assays based on plasma-derived FXII, Silverberg and Kaplan suggested that if single-
chain FXII had activity, it is weak, and calculated a limit on its ability to cleave the tripeptide S-2302 at
<4200-fold that of FXIIa [27].
In vivo, polymeric anions may serve as counterparts to the non-biologic substances traditionally used to
study contact activation. One of the best characterized is Poly-P, polymers of inorganic phosphate that
produce procoagulant effects in plasma including induction of contact activation [17,21,25,41]. Engel et al.
recently reported that FXII bound to Poly-P chains of the size released by platelets cleaves S-2302 and
activates PK and FXI without undergo conversion to FXIIa [31], indicating Poly-P-binding induces
conformational changes in single-chain FXII that confer activity. A striking finding in their study, which
conflicts with the data presented here, was that the amidolytic activities of FXIIa and Poly-P-bound FXII
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were comparable, suggesting conversion to FXIIa is not necessary for full (or substantial) elaboration of
protease activity. These experiments, and earlier work, used plasma FXII, making it difficult to exclude
effects from FXIIa, either as an initial contaminant or as a product generated during reactions. We
addressed this issue with recombinant FXII that cannot be converted to FXIIa. Our results show that
single-chain FXII has activity and that Poly-P enhances that activity toward the macromolecular substrates
PK, FXII and FXI. However, there are important differences between our results and those reported by
Engel et al., and they support different mechanisms for the role of cofactors such as Poly-P in FXII activity.
Differences between recombinant and plasma-derived FXII, either as a consequence of the substitutions we
introduced or subtler factors such as variance in post-translational modification, may partly explain the
weaker activity we detected for single chain FXII, compared with the activity for plasma FXII reported by
Engel et al. However, this would not explain the different behaviors observed for plasma FXII in the
presence of Poly-P.
Members of the trypsin-like protease family are usually secreted as inactive single-chain zymogens that
require internal proteolysis after Arg15 (chymotrypsin numbering) for activity [42]. Upon cleavage, the
new catalytic domain N-terminus (residue 16) forms a salt-bridge with Asp194, creating a functional
substrate recognition site. Consistent with this, we observed that increased rates of S-2302 cleavage by FXII
(plasma or recombinant) in the presence of Poly-P are associated with conversion to FXIIa. Arg353 in
human FXII corresponds to chymotrypsin Arg15 [36,38], and replacing it blocks Poly-P-mediated FXII
autocatalysis and the associated increase in amidolytic activity. These findings support the premise that
polyanion-induced elaboration of full FXII activity involves cleavage after Arg353 [27,28]. Our data with
plasma-derived and recombinant FXII-WT are in disagreement with those of Engel et al. on this point.
Perhaps differences in preparative techniques for Poly-P, or methods for detecting FXIIa contribute to the
discrepancy. We observed that Poly-P-based reactions behave differently depending on buffer conditions,
which may be relevant. However, it is worth noting that forms of FXII that do not form FXIIa did not
reconstitute FXII-deficient mice in a thrombosis model in which FXII and Poly-P play prominent roles
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[17,25]. This argues against a mechanism in which binding of a cofactor converts FXII to a fully or
substantially active protease without cleavage after Arg353, and is consistent with the marked decrease in
activity of the natural variant FXII Locarno, in which proline replaces Arg353 [43].
Single chain FXII-T cleaves S-2302 and activates PK without adding Poly-P or a surface, suggesting it has
a low level of proteolytic activity when not surface-bound. Poly-P does, however, enhance PK activation,
and facilitates FXII and FXI activation by FXII-T. There may be multiple effects that contribute to the
mechanism involved. First, Poly-P-bound FXII-T may assume a conformation that enhances extended
interaction with macromolecular substrates. It is also likely that the substrate (PK, FXII or FXI) is altered
upon binding to Poly-P, exposing activation cleavage sites. Furthermore, the size dependence of the Poly-
P-effect [41,44] points to facilitation of protease and substrate binding in proximity to each other through
a bridging (template) mechanism.
There is precedent for plasma serine proteases having activity in their single-chain forms, a property
referred to as low zymogenisity. Single chain tissue plasminogen activator (tPA) is 8-fold less active against
tripeptide substrates and 20-50-fold less active towards plasminogen than two-chain tPA [45], but in the
presence of fibrin both forms cleave plasminogen similarly. Renatus et al. proposed that a salt bridge
between Lys156 and Asp194 in tPA (Fig8A) not found in most trypsin-like proteases contributes to
formation of a functional active site in the single-chain protein [46]. Single-chain urokinase, also has
activity toward plasminogen in the presence of fibrin and, like tPA, has lysine at position 156 [47]. Gln156
in FXII cannot form a stabilizing salt bridge with Asp194, but it may provide weak stabilization through
hydrogen bonding interactions. In addition to forming a salt bridge with Lys156, the carboxylate group of
Asp194 in tPA forms hydrogen bonds with the main-chain nitrogen atoms of Gly142 and Cys191 (Fig.8A).
A homology model of FXII-T based on the tPA structure reveals that the FXII Asp194 carboxylate can
form the same hydrogen bonds (Fig.8B) [48]. Furthermore, because of additional hydrogen bond with the
side-chain of Gln156, there is no impediment to oxyanion hole formation. Gln156 would be less effective
at stabilizing Asp194 in FXII-T than the N-terminal Val16 in FXIIa, consistent with the lower catalytic
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activity of FXII-T. Recently the crystal structure of FXII catalytic domain with Arg-Ser blocking the N-
terminus (FXIIc) was reported [49]. FXIIc has a zymogen-like conformation, lacking the oxyanion hole,
and Asp194 interacts with Arg73 in a configuration similar to the zymogen triad described for
chymotrypsinogen (Fig. 8C) [50,51]. This suggests a complex interplay of factors, including
conformational changes within FXII induced by interactions with substrates, determine formation of a
productive FXII-T enzyme-substrate complex, as has been proposed for other members of the trypsin-like
protease family [52].
Our results support a model for contact activation that does not require pre-existing FXIIa or -kallikrein.
Single-chain FXII would catalyze initial FXII and PK conversion to FXIIa and -kallikrein upon surface
exposure. The relatively low activity of single-chain FXII suggests that it is FXIIa and -kallikrein that
are responsible for subsequent acceleration of contact activation. This is consistent with the observation
that progress curves for FXII autoactivation fit models based on initiation by traces of FXIIa [27,28].
Single-chain FXII activity is relevant early in contact activation when FXIIa concentration is low, but is
progressively less important as FXIIa accumulates. Finally, our plasma-based studies indicate that while
surface-bound single-chain FXII activates FXI, FXIIa is a considerably better activator, supporting the
premise that the procoagulant and prothrombotic activities of FXII are mediated largely, if not exclusively,
through FXIIa. The observation that single-chain FXII activates PK has interesting implications. While
the reaction is several orders of magnitude less efficient than for FXIIa activation of PK, the plasma PK
concentration (~600 nM) is near Km for fluid phase activation by FXII-T. Furthermore, under normal
conditions the plasma concentration of FXII (~400 nM) is probably several orders of magnitude higher than
that of FXIIa. This suggests that the relatively high plasma FXII level could compensate for the weak
specific activity of single-chain FXII toward PK. Given this, single-chain FXII activity may contribute to
the basal reciprocal turnover of FXII and PK observed in vivo [19].
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Figure 1. Recombinant Contact Factors. (A) Schematic diagrams of contact factors showing non-
catalytic (white boxes) and catalytic (gray boxes) domains. Positions of active site serine residues are
indicated by black bars. Sites of proteolysis during activation are indicated by arrows, with black arrows
indicating sites of cleavage required for full protease activity. FXII is an 80 kDa polypeptide that may be
cleaved at three locations. Cleavage after Arg353 converts FXII to FXIIa. Cleavage of FXIIa after
Arg334 separates the non-catalytic and catalytic domains, forming FXIIa. The importance of cleavage
after Arg343 is not clear. The FXII non-catalytic domains are the fibronectin type 2 (F2), epidermal growth
factor (EGF), fibronectin type 1 (F1), and kringle (K) domains, and a proline–rich region (PRR). PK is a
93 kDa polypeptide that is cleaved after Arg371 to form -kallikrein (-Kal). A second cleavage after
Arg140 produces -kallikrein (-Kal). FXI is a homodimer of 80 kDa polypeptides. It is converted to FXIa
by cleavage after Arg369. The non-catalytic portions of PK and FXI contain four apple domains, designated
A1 to A4. (B) Coomassie blue-stained non-reducing SDS-PAGE of purified FXII (left panel) and PK (right
panel) containing ~2 g samples per lane. Positions of molecular mass standards in kilodaltons are shown
to the left of the images.
Figure 2. FXII autoactivation and activation by kallikrein. (A) Plasma FXII (200 nM) was incubated in
standard buffer without Poly-P (–Poly-P) or presence of 70 M Poly-P (+ Poly-P). At the indicated times,
samples were removed from the reaction into reducing sample buffer, size fractionated on a 10%
polyacrylamide-SDS gel and stained with Coomassie Blue. Positions of standard for single chain FXII and
the heavy chain (HC) and light chain (LC) of FXIIa are shown at the right of each panel. (B) Chromogenic
substrate assay for FXIIa activity for the fractions shown in the gel in panel A. Reactions were run in the
presence () or absence () of 70 M Poly-P. (C) Recombinant FXII species (200 nM) incubated in the
absence of an activator (control - left column), in the presence of 70 M Poly-P (center column), or in the
presence of 50 nM -kallikrein without a surface (right column). At the indicated times, samples were
removed into reducing sample buffer. Samples were size fractionated by SDS-PAGE, followed by western
blot analysis with a polyclonal anti-human FXII IgG. For panels A and C, positions of standards for FXII
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and the heavy chain (HC) and light chain (LC) of FXIIa are indicated at the right of each image. (D)
Recombinant FXII species (200 nM) were incubated in the presence of 70 M Poly-P and 200 M S-2302.
Changes in OD 405 nm were continuously monitored on a microplate reader. (E) FXII (200 nM) was
incubated with 50 nM -kallikrein for 120 min at 37 C in the absence of a surface. Kallikrein was inhibited
with IgG H03 and FXIIa cleavage of S-2302 (200 M) was measured.
Figure 3. Reciprocal activation of FXII and PK in the absence of a surface. (A to C) FXII (200 nM)
and PK (200 nM) species were incubated at 37 C. At indicated time points, samples were removed into
reducing (A and C) or non-reducing (B) sample buffer, size fractionated by SDS-PAGE and analyzed by
western blot using (A and C polyclonal IgG to FXII (XII) or PK) or (B) monoclonal IgGs that preferentially
recognize the activated forms FXIIa (D06) and kallikrein (H03). (A and B) Reciprocal activation of plasma
FXII and PK. (C) activation of PK-WT by recombinant FXII species. For panels A and C, positions of
standards for FXII (XII) and the heavy chain (HC) and light chain (LC) of FXIIa; and standards for PK
(PK), the heavy chain (HC) and light chain (LC) of -kallikrein, and a fragment of the heavy chain of -
kallikrein () are indicated at the right of each image. For panel B, positions of standards for FXIIa,
FXIIa, -kallikrein (-kal) and -kallikrein (-kal) are indicated on the right.
Figure 4. Cleavage of S-2302 and PK by FXII species. (A) 200 nM FXII-WT (WT), FXII-R353A , FXII-
T (T) or FXII-S544A were incubated with 200 M S-2302 in standard buffer in the absence of a surface.
Continuous formation of amidolytic activity was monitored at 405 nm. (B and C) Varying concentration of
S-2302 (1.6-1000 M) were incubated with (B) 5 nM FXIIa or (C) 200 nM FXII-T in the absence of a
surface. Changes in OD 405 nm/min were measured on a plate reader and converted to pNA generated per
minute. Each point is a mean  one SD for three separate experiments. (D) Same as reactions described in
panel A except that incubations were conducted in the presence of a surface (PTT-A reagent, 10% final
volume). Note that PTT-A reagent only increases the amidolytic activity of WT-FXII, compared to
reactions in panel A because, of the four FXII species tested, it is the only one that is cleaved after Arg353
and has an active site serine at residue 544. (E) PK-WT (200 nM) was incubated with 200 nM FXII-WT,
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FXII-R353A, FXII-T, FXII-S544A or control vehicle (C). Generation of kallikrein (or kallikrein and
FXIIa in the case of FXII-WT) was continuously monitored by cleavage of S-2302 (200 M). (F and G)
Varying concentration of PK were incubated with (F) 25 pM FXIIa or (C) 15 nM FXII-T in the absence
of a surface. Kallikrein generation was determined by measuring the rate of S-2302 (200 M) cleavage.
Each point is a mean  one SD for three separate experiments. (H) Generation of kallikrein from PK-WT
(200 nM) was followed by continuous monitoring of S-2302 (200 M) cleavage in the presence or absence
of a surface (70 M Poly-P), and in the presence or absence of 200 nM FXII-T (T). (I) Kinetic parameters
for cleavage of S-2302 and PK by FXIIa or FXII-T determined from the curves in panels B, C, F and G.
Figure 5. Activation of FXII and FXI by single chain FXII. (A) Western blots of a mixture of FXII-T
(200 nM) and FXII-S544A (200 nM) in the absence of a surface (No Surface), or in the presence of PTT-
A reagent (25% final volume) or Poly-P (70 M). At indicated times samples were removed into non-
reducing sample buffer, size fractionated by SDS-PAGE and analyzed by western blot using IgG D06 which
recognizes formation of the FXIIa active site. The bottom row shows results for FXII-S544A and FXII-T
incubated separately with 70 M Poly-P. (B) FXI-S557A (30 nM) was incubated with 200 nM FXII-WT,
FXII-T or FXII-S544A in the absence (top row) or presence (bottom row) of 70 M Poly-P. At indicated
times samples were removed into non-reducing sample buffer, size fractionated by SDS-PAGE and
analyzed by western blot using a goat-anti-human FXI polyclonal IgG.
Figure 6. Surface-initiated clotting and thrombin generation in human plasma. (A) Clotting times in
an aPTT assay for pooled normal plasma (PNP), FXII-deficient plasma (FXII DP) or FXII-deficient plasma
supplemented with recombinant FXII species (FXII added to FXII DP). Each symbol indicates one clotting
time and the horizontal bars indicate means for each group  1 SD. (B) Thrombin generation in FXII-
deficient plasma supplemented with PTT-A reagent in the absence of FXII (No XII dotted line) or in the
presence of plasma FXII (dashed line) or FXII-WT (solid line). (C) Thrombin generation in FXII-deficient
plasma supplemented with PTT-A reagent and FXII-WT (solid line), FXII-T (dashed line) or FXII-S544A
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(dotted line). (D) Reactions for FXII-WT and FXII-T shown in panel C run in the presence of CTI or anti-
FXI IgG 01A6. For all panels, results represent means for three runs.
Figure 7. Mouse carotid artery thrombosis model. FXII-deficient C57Bl/6 mice were infused with 100
l of PBS (C) or 100 l of PBS containing 25 g of FXII-WT, FXII-R353A, FXII-T or FXII-S544A.
Thrombus formation was induced by application of two pads saturated with 5% FeCl3 to opposite sides of
the carotid artery for three min. Flow through the artery was recorded for 30 minutes. The percent of animals
with occluded arteries 30 minutes after FeCl3 application are shown in the bar graph (n = 9 for each bar).
Representative plasma samples from test mice were analyzed by western blot to make certain that FXII was
still in the circulation at the end of the study. Abbreviations: C – FXII control; NP – normal mouse plasma;
DP – FXII deficient mouse plasma. Each number indicates a separate animal.
Figure 8. Comparison of tPA and FXII structures. Shown are stick diagrams of S1 pocket structures
with hydrogen bonds and electrostatic interactions shown as dotted lines (purple). In panels A and B the
position of the oxyanion hole is indicated by the juxtaposed blue spheres that represent the nitrogen atoms
of Ser195 and Gly193. (A) Single-chain tPA active S1 pocket crystal structure (pdb:1BDA) is shown with
Asp194 stabilized by the salt bridge formed with Lys156 (Indicated by + and  symbols), and also by
hydrogen bonds with the main-chain nitrogens of Gly142 and Cys191. The cyan stick figure represents the
side-chain of the arginine P1 residue of the tPA inhibitor dansyl-Glu-Gly-Arg-chloromethylketone. (B)
Homology model (SWISS-MODEL [48]) of the S1 pocket of FXII-T based on the tPA crystal structure
where Gln156 forms a hydrogen bond to the Asp194 carboxylate group. The side-chain shown in cyan
represents the P1 arginine of a substrate (PK or FXI). (C) Crystal structure (pdb:XDE) showing the inactive
zymogen conformation of FXIIc where the oxyanion hole is absent (all figures prepared with PyMOL
Molecular Graphics System, Version 1.8 Schrödinger, LLC).
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